Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2478MR)

This product GTTS-WQ2478MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2478MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ13703MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ2110MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ202MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ2775MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ14144MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ8526MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ12676MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-18R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW